TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06627829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgically facilitated orthodontics therapy (SFOT) using allograft
Description: Participants will receive Surgically facilitated orthodontics therapy (SFOT) along with bone grafting using particulate allograft and collagen membrane, prior to orthodontics treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgically facilitated orthodontics therapy (SFOT) using xenograft
Description: Participants will receive SFOT using particulate xenograft and collagen membrane, prior to orthodontics treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will have conventional orthodontics treatment with Invisalign aligners, without any surgical intervention
Study: NCT05252377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: 1. The patient will be asked to close their eyes~2. He will be asked to relax his head and neck in a semi-sitting position in bed~3. The patient will be asked to breathe through the nose for 3 seconds by counting~4. Then he will be told to hold his breath for 3 seconds~5. As the last step, he will be asked to breathe out again in 3 seconds.
Study: NCT06732284

Intervention type: OTHER
Intervention: Psychomotor vigilance task
Description: Five PVT tests (before sleep at 7pm, 7am, 7:30am, 8am and 11am). The PVT is a 10-minute test designed to assess the vigilance and sustained attention by measuring reaction times (RT) to visual stimuli. During the test, participants are required to monitor the computer screen and press the response button as soon as a millisecond counter appears which will stop the counter and display the RT in milliseconds. The stimuli are randomly presented.

Intervention type: OTHER
Intervention: Psychomotor vigilance task
Description: Five PVT tests (before sleep at 7pm, 7am, 7:30am, 8am and 11am). The PVT is a 10-minute test designed to assess the vigilance and sustained attention by measuring reaction times (RT) to visual stimuli. During the test, participants are required to monitor the computer screen and press the response button as soon as a millisecond counter appears which will stop the counter and display the RT in milliseconds. The stimuli are randomly presented.

Intervention type: OTHER
Intervention: Psychomotor vigilance task
Description: Five PVT tests (before sleep at 7pm, 7am, 7:30am, 8am and 11am). The PVT is a 10-minute test designed to assess the vigilance and sustained attention by measuring reaction times (RT) to visual stimuli. During the test, participants are required to monitor the computer screen and press the response button as soon as a millisecond counter appears which will stop the counter and display the RT in milliseconds. The stimuli are randomly presented.

Intervention type: OTHER
Intervention: Video-polysomnography
Description: Performed overnight as part of routine care (11 p.m. to 7 a.m.).

Intervention type: OTHER
Intervention: Video-polysomnography
Description: Performed overnight as part of routine care (11 p.m. to 7 a.m.).

Intervention type: OTHER
Intervention: Video-polysomnography
Description: Performed overnight as part of routine care (11 p.m. to 7 a.m.).

Intervention type: OTHER
Intervention: Sleep and activity monitoring
Description: Actimeter and sleep diary to assess the sleep-wake patterns of the participants in their natural environments over a two-week period.

Intervention type: OTHER
Intervention: Sleep and activity monitoring
Description: Actimeter and sleep diary to assess the sleep-wake patterns of the participants in their natural environments over a two-week period.

Intervention type: OTHER
Intervention: Sleep and activity monitoring
Description: Actimeter and sleep diary to assess the sleep-wake patterns of the participants in their natural environments over a two-week period.
Study: NCT06741852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nCLE assisted endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy via a tunnel
Description: Patients received 2.5mL of 10% Fluorescite intravenously during nCLE. The CLE probe was preloaded into a puncture dilation catheter and locked into position with 2mm being exposed beyond the tip. puncture dilation catheter. The lymph node was punctured and the needle positioned at its center. The probe was advanced and locked, and the needle was advanced to the contralateral edge of the lymph node. Image acquisition began at the lymph node capsule, and then the subcapsular region, followed by the cortical sinus. When the image showed granuloma or malignant characteristics, the location will be recorded in EBUS, and retract the CLE probe, leaving the sheath of puncture dilation catheter as a tunnel between airway wall and target lymph node. Then, a 1.1-mm cryoprobe was inserted into the target lymph node through this tunnel under the EBUS guidance. The probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy via a tunnel
Description: First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Broncus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
Study: NCT06742489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation device
Description: T-PTNS primarily delivers electrical stimulation to the sacral voiding center via the tibial nerve through the S2-S4 sacral plexus via skin-surface electrodes to improve patients' symptoms of urinary frequency, urgency, and urge incontinence.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group device
Description: The device in the sham group is manufactured by the same company and has the same appearance, display interface, and operation method as the device in the treatment group. These devices have the output circuit disconnected and no actual current output.
Study: NCT06741527

Intervention type: DEVICE
Group type: OTHER
Intervention: Integrity Implant System
Description: Integrity Implant System used for Rotator Cuff Repair
Study: NCT06741800

Intervention type: DRUG
Intervention: ACARIZAX®️
Description: ACARIZAX®️：The recommended dose for adults (18-65 years) is one freeze-dried tablet (12 SQ-HDM) daily, placed under the tongue.
Study: NCT06742372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined inspiratory and aerobic exercise training
Description: combined inspiratory and aerobic exercise training will be performed in healthy individuals
Study: NCT05142085

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nano-PSO
Description: This active treatment will be delivered to 3 out of 5 patients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nano-PSO
Description: This active treatment will be delivered to 3 out of 5 patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: This treatment will be assigned to 2 out of 5 patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: This treatment will be assigned to 2 out of 5 patients
Study: NCT06742372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: aerobic exercise training will be performed in healthy individuals
Study: NCT06743243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan OD tab. 50 mg PO + Saline 20ml IV, one hour before general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 20mg/10ml+saline 10ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tegoprazan OD tab. 50 mg placebo PO + Saline 20ml IV, one hour before general anesthesia.
Study: NCT06742528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: ferrous sulphate in a dose of 6mg/kg/day of elemental iron once daily for 8 weeks orally in syrup form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Polymaltose Complex
Description: Iron Polymaltose complex in a dose of 6mg/kg/day of elemental iron once daily orally for 8 weeks.
Study: NCT06742905

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Robot-guided echo
Description: This echo will be performed by a remote sonographer, though a robot

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard echocardiogram
Description: Echocardiogram acquired by a sonographer at the patient's bedside
Study: NCT06741774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular Meshwork Microstent Drainage System
Description: The device is implanted on the functional trabecular meshwork with head in schlemm canal and tail in anterior chamber. There is a hollow tube connecting schlemm canal and anterior chamber. The device can promote external drainage of aqueous humor to reduce intraocular pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: Eyes with OAG and cataracts randomly divided into control group that were planned for phacoemulsification alone.
Study: NCT06741878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Involves participants engaging in physical training group sessions in light-to-moderate intensity.
Study: NCT05161780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
Study: NCT06449014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-implants assisted maxillary expansion
Description: The intervention involved the placement of orthodontic mini-screws in the patient's palate, varying in diameter from 2 to 2.3 mm and in length from 11 to 15 mm. After mini-screw insertion, another intraoral scan was taken for the fabrication of the appliance. Approximately three weeks later, the expander was placed in the patient's palate, and maxillary expansion was initiated immediately afterward according to the chosen protocol.
Study: NCT06741878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Involves participants engaging in physical training group sessions in light-to-moderate intensity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial
Description: Involves participants engaging in selected board and card games which require cognitive and socialization skills to play in a group setting of 2-4 people.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial
Description: Involves participants engaging in selected board and card games which require cognitive and socialization skills to play in a group setting of 2-4 people.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional
Description: Involves participants attending dietary classes taught by a certified dietitian, including individualized consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional
Description: Involves participants attending dietary classes taught by a certified dietitian, including individualized consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional
Description: Involves participants attending dietary classes taught by a certified dietitian, including individualized consultation.
Study: NCT06508710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
Study: NCT06449014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-implants assisted maxillary expansion
Description: The intervention involved the placement of orthodontic mini-screws in the patient's palate, varying in diameter from 2 to 2.3 mm and in length from 11 to 15 mm. After mini-screw insertion, another intraoral scan was taken for the fabrication of the appliance. Approximately three weeks later, the expander was placed in the patient's palate, and maxillary expansion was initiated immediately afterward according to the chosen protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-implants assisted maxillary expansion
Description: The intervention involved the placement of orthodontic mini-screws in the patient's palate, varying in diameter from 2 to 2.3 mm and in length from 11 to 15 mm. After mini-screw insertion, another intraoral scan was taken for the fabrication of the appliance. Approximately three weeks later, the expander was placed in the patient's palate, and maxillary expansion was initiated immediately afterward according to the chosen protocol.
Study: NCT06508710

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
Study: NCT06472167

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercises
Description: Breathing exercises as diaphragmatic breathing exercises and pursued lip breathing and incentive spirometry
Study: NCT05114460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naloxone
Description: Intranasal Naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Intranasal Naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Intranasal Naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Intranasal Naloxone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marijuana
Description: Vaped Marijuana

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marijuana
Description: Vaped Marijuana

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marijuana
Description: Vaped Marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Vaped Marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Vaped Marijuana
Study: NCT04896008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04613453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Infusion
Description: Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Infusion
Description: Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
Study: NCT05879107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV20
Description: One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV20
Description: One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
Study: NCT05672186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full-service market intervention
Description: Full-service mobile market implementation: the market will visit intervention sites weekly. The market will carry items from all food groups including fresh, frozen and canned fruits and vegetables, whole grains, dairy/ dairy substitutes, proteins (e.g., frozen meat/fish, beans, eggs), and dry goods (e.g., cooking oil, spices). Prices on the market are affordable, approximately 10% lower than grocery stores.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT05996185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH Protocol
Description: EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
Study: NCT05407935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTivity
Description: Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxercise
Description: Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
Study: NCT04660201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AV7909
Description: AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
Study: NCT05239416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
Study: NCT05013996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIDSA
Description: Multidimensional Inventory of Development, Sex, and Aggression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual methods of evaluation
Description: Usual methods of evaluation of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
Study: NCT06196645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention Based on Theory of Planned Behavior
Description: The content of the intervention plan to be implemented consists of the following components: (I) transferring knowledge about health-related physical fitness and physical activity, (II) taking individual responsibility for physical activity monitoring and simple individual planning, (III) including in the program the types of activities that female adolescents choose and declare that they would enjoy participating in.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention Based on Theory of Planned Behavior with Parental Participation
Description: The content of the intervention plan to be implemented consists of the following components: (I) transferring knowledge about health-related physical fitness and physical activity, (II) taking individual responsibility for physical activity monitoring and simple individual planning, (III) including in the program the types of activities that female adolescents choose and declare that they would enjoy participating in. In this group, at least one parent will also be involved.
Study: NCT06285617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-week predisone+1-week celecoxib
Description: 20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib (a type of nonsteroidal anti-inflammatory drug) on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
Study: NCT06108479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6215
Description: Immunotherapy (cytokine) targeting effector cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6215
Description: Immunotherapy (cytokine) targeting effector cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6215
Description: Immunotherapy (cytokine) targeting effector cells.
Study: NCT06285617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-weeks predisone
Description: 20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
Study: NCT04150458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorocholine PET/CT.
Description: 18F-fluorocholine positron emission tomography / computed tomography